

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED.
SECRETARY OF THE SENATE
03 FEB 13 PM 5:09

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Hogan & Hartson L.L.P.			
2. Address <input type="checkbox"/> Check if different than previously reported 555 13th Street, N.W. Washington, DC 20004-1109			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Maruyama, Warren H.	Telephone 202/637-5709	E-mail (optional)	5. Senate ID # 18422-
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research Manufacturers of America (PhRMA)			6. House ID # 30470

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐


10. Check if this is a Termination Report ☐ ⇒ Termination Date _____

11. No Lobbying ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>260,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
--	--

Signature



Printed Name and Title Maruyama, Warren H. Partner

LD-2 (REV. 6/98)

P

Registrant Name Hogan & Hartson L.L.P. Client Name Pharmaceutical Research Manufacturers of Am

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001
H.R. 3448, Public Health Security and Bioterrorism Response Act of 2001
S. 1715/S. 1765 Bioterrorism Preparedness Act of 2001
S. 754, Drug Competition Act of 2001
S. 812/H.R. 1862, Greater Access of Affordable Pharmaceutical Act of 2001

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Beier, David W.	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature



Date 02/12/2003

Printed Name and Title Maruyama, Warren H. Partner

Form LD-2 (Rev.6/98)

Page 5

Registrant Name Hogan & Hartson L.L.P. Client Name Pharmaceutical Research Manufacturers of Am

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

U.S. -Asia pharmaceutical trade, U.S. -Japan Regulatory Reform Initiative, U.S. - Singapore FTA, China WTO, U.S. - Australia FTA negotiations, Asian intellectual property rights

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. Senate, Office of the United States Trade Representative, Commerce Department, Department of State, Food & Drug Administration, U.S. House of Representatives

Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Archibald, Jeanne S. Horton, Linda R. Maruyama, Warren H.	Partner Partner Partner

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature

Date 02/12/2003

Printed Name and Title Maruyama, Warren H. Partner

Form LD-2 (Rev.6/98)

Page

Registrant Name Hogan & Hartson L.L.P. Client Name Pharmaceutical Research Manufacturers of An

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 2729 and other legislation relating to Medicare prescription drug benefits
Implementation of Medicare Outpatient Prospective Payment System

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Department of Health and Human Services, U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Langbein, Stuart M. Vickery, Ann Morgan	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature



Date 02/12/2003

Printed Name and Title Maruyama, Warren H. Partner

Form LD-2 (Rev.6/98)

Page

Registrant Name Hogan & Hartson L.L.P. Client Name Pharmaceutical Research Manufacturers of Am

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City State/ Zip:

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)
		City: State: Zip: Country:

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
		City: Country:	

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant affiliated organization

Signature

[Handwritten Signature]

Date

Signature _____ Date _____

Printed Name and Title Maruyama, Warren H. Partner

Form LD-2 (Rev. 6/98)

Page 1